Evidence map›Paper›PMID 32737142›Full record

ArticleJournal for immunotherapy of cancer2020

Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141

Kelly-Anne Masterman, Oscar L Haigh, Kirsteen M Tullett, Ingrid M Leal-Rojas, Carina Walpole, Frances E Pearson, Jonathon Cebon, Christopher Schmidt, Liam O'Brien, Nikita Rosendahl and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Human CD34Cellular and molecular life sciences : CMLS · 2023
    Article
  17. Review
  18. Article
  19. Review
  20. Engaging innate immunity in HIV-1 cure strategies.Nature reviews. Immunology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Kelly-Anne Masterman *Mater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Oscar L Haigh *Mater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Kirsteen M TullettMonash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
Ingrid M Leal-RojasMater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Carina WalpoleMater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Frances E PearsonMater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Jonathon CebonDepartment of Hematology and Oncology, Olivia Newton John Cancer Research Institute, Heidelberg, Victoria, Australia.
Christopher SchmidtMater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Liam O'BrienMater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Nikita RosendahlMater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Ghazal DarajMater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia.
Irina CaminschiMonash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
Eric H GschwengDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
Roger P HollisDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
Donald B KohnDepartment of Microbiology, Immunology and Molecular Genetics, University of California, Los Angeles, Los Angeles, California, USA.
Mireille H LahoudMonash Biomedicine Discovery Institute and Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, Australia.
Kristen J RadfordMater Research Institute, University of Queensland, Woolloongabba, Queensland, Australia kristen.radford@mater.uq.edu.au.ORCID 0000-0001-6512-6323
The University of Queensland · AUAustralian Regenerative Medicine Institute · AUUniversity of California, Los Angeles · USOlivia Newton-John Cancer Wellness & Research Centre · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDendritic cells (DCs) are crucial for the efficacy of cancer vaccines, but current vaccines do not harness the key cDC1 subtype required for effective CD8

methodsHuman anti-CLEC9A, anti-DEC-205 and isotype control IgG4 antibodies were genetically fused to NY-ESO-1 polypeptide. Cross-presentation to NY-ESO-1-epitope-specific CD8

resultsCLEC9A-NY-ESO-1 antibodies (Abs) were effective at mediating delivery and cross-presentation of multiple NY-ESO-1 epitopes by CD141

conclusionsThese data advocate human CLEC9A-NY-ESO-1 Ab as an attractive strategy for specific targeting of CD141

Indexed as

AnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesDendritic CellsFemaleHealthy VolunteersHumansLectins, C-TypeMembrane ProteinsMiceReceptors, MitogenThrombomodulinAntigens, NeoplasmCLEC9a protein, humanCTAG1B protein, humanLectins, C-TypeMembrane ProteinsReceptors, MitogenTHBD protein, humanThrombomodulindendritic cellsimmunogenicity, vaccineimmunotherapymelanoma

Identifiers

PMID32737142
PMCPMC7394304
OpenAlexW3046666310

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.